Literature DB >> 22120329

Survival and functional outcome after surgical resection of intramedullary spinal cord metastases.

David A Wilson1, David J Fusco, Timothy D Uschold, Robert F Spetzler, Steve W Chang.   

Abstract

OBJECTIVE: Intramedullary spinal cord metastasis (ISCM) is a rare manifestation of systemic cancer and data about the optimal management of these lesions are lacking. To clarify the role of surgery, we investigated survival and neurological outcomes after surgical resection of ISCMs.
METHODS: Between 2003 and 2010, we surgically treated 10 ISCMs in 9 patients. For each patient, we retrospectively collected the following data: demographic variables, history of prior cancer, site of primary cancer, extent of cancer on presentation, degree of resection, preoperative and postoperative spinal cord impairment (American Spinal Injury Association [ASIA] grade), and postoperative survival. We investigated the relationship between these variables, overall survival, and preservation of function.
RESULTS: Eight ISCMs were treated with gross total resection and two were treated with subtotal resection. Overall postoperative survival was 6.4 ± 9.4 months (mean ± standard deviation), with one patient still alive at last follow-up. Patients with a diagnosis of melanoma had higher mean survival than those with nonmelanoma histology (20.5 ± 13.4 vs. 2.4 ± 1.7 months, P < 0.01). Degree of resection, number of organ systems affected, ambulatory status, and ASIA grade pre operatively or postoperatively, were not significantly associated with survival. Of the nine patients, seven (78%) demonstrated no change in ASIA grade postoperatively, one (11%) improved, and one patient (11%) deteriorated. All patients who were ambulatory preoperatively remained ambulatory postoperatively and at last follow-up.
CONCLUSIONS: Although ISCM is associated with poor prognosis, survival appears to be greater in patients with melanoma. Surgical resection does not appear to significantly lengthen survival but may be indicated to preserve ambulatory status in symptomatic patients.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22120329     DOI: 10.1016/j.wneu.2011.07.016

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  6 in total

1.  Intramedullary spinal cord metastases: prognostic value of MRI and clinical features from a 13-year institutional case series.

Authors:  F E Diehn; J B Rykken; J T Wald; C P Wood; L J Eckel; C H Hunt; K M Schwartz; R K Lingineni; R E Carter; T J Kaufmann
Journal:  AJNR Am J Neuroradiol       Date:  2014-11-13       Impact factor: 3.825

2.  Intramedullary spinal cord metastasis from colon cancer: analysis of 19 reported cases.

Authors:  Tai-Hsin Tsai; I-Cheng Lin; Pei-Chen Lin; Chieh-Hsin Wu; Chih-Lung Lin; Yu-Feng Su
Journal:  Spinal Cord Ser Cases       Date:  2016-01-07

3.  Intramedullary spinal cord metastasis from pancreatic neuroendocrine tumor.

Authors:  Jung Ho Kim; Chang Lim Hyun; Sang Hoon Han
Journal:  World J Gastroenterol       Date:  2014-10-14       Impact factor: 5.742

Review 4.  Intramedullary Spinal Cord Tumors: Part I-Epidemiology, Pathophysiology, and Diagnosis.

Authors:  Dino Samartzis; Christopher C Gillis; Patrick Shih; John E O'Toole; Richard G Fessler
Journal:  Global Spine J       Date:  2015-03-31

5.  Intramedullary spinal cord metastasis in malignancies: an institutional analysis and review.

Authors:  Jincai Lv; Bailong Liu; Xiaoyue Quan; Cheng Li; Lihua Dong; Min Liu
Journal:  Onco Targets Ther       Date:  2019-06-21       Impact factor: 4.147

6.  Intramedullary Spinal Cord Metastases of Malignant Melanoma: A Rare Case Report on Paraplegia in Palliative Care.

Authors:  Rutula Sonawane; Arunangshu Ghoshal; Anuja Damani; MaryAnn Muckaden; Jayita K Deodhar
Journal:  Indian J Palliat Care       Date:  2019 Jul-Sep
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.